← BackJOHNSON & JOHNSON · DrugmakersJNJ
Low riskNext report: Around Jan 20, 2027 (est.)
The short versionA high-quality, profitable business with steady sales.
Going well
- Profitable every year for 10 years
- Brings in more cash than it spends
- Buying back shares: share count down 8.8% in 3 years
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 1.9% to their holdings in the quarter ending June 2026 (2180 bought, 1990 sold)
- Held by George Soros (Soros Fund), Ray Dalio (Bridgewater)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$266.37+0.9% that day
- Company value
- $641.2B
- Share price times all shares
- Price vs profit (P/E)
- 40.4x
- You pay about $40 for each $1 of yearly profit
- Price vs sales
- 6.8x
- Company value is 6.8 times a year of sales
- Dividend yield
- 1.9%
- Yearly dividend as a share of today's price
- Cash vs value
- 3%
- Cash as a share of company value
- Debt vs value
- 6%
- Debt as a share of company value
From JNJ's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Profit, Sep '26$210.0M-96% vs a year earlier
Dec '23Tap a barSep '26
Last 12 months: $16.1B, down 36% from the 12 months before.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- PassReturn on equity 15%+Earns a lot on the money owners have in the business.35.0%
- MissDebt under half of equityNot relying on borrowed money.0.51x equity
- PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.28.5%
- PassProfitable every yearSteady profits, not one good year.10 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$19.7B
- PassShare count not growingNot diluting owners. Falling means buybacks.-8.8% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.67.9%
- Revenue
- $94.2B
- +6.0% vs prior year
- 5-year growth
- +2.7%/yr
- revenue, per year
- Total debt
- $41.4B
- 0.51x equity
- Current ratio
- 1.03x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Sep 27, 2026- EPS
- $0.09
- vs $2.12
- Free cash flow
- $6.4B
- Share count
- +0.8%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
55/ 100
- This week
- 2
- Normal week
- 1.7
- vs normal
- 1.2x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
■Steady+1.9%Institutions added 1.9% to their holdings. 2180 bought, 1990 sold.
Shares held by institutions1.80B
Sep '24Jun '26
Share count growthYearly rate, last 3 years
0.0%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
0.4x · $35.8B debtShares outstandingLatest reported
2.4BNext reportAround Jan 20, 2027 (est.)Estimated from the same quarter last year
- Results filedOct 13
- Results filedJul 15
- Results filedApr 14
- Results filedJan 21
- Results filedOct 14, 2025
Flags and big holders
Offerings 6 months, flags 12 months, holders 90 days
No offerings, red flags or new big holders. Clean record.
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
Latest filings
Straight from SEC EDGAR
Stock awardMarillyn A HewsonDirector
181 shares at $276.31 · $50K
- +1% of holdings
- Now owns 16,049 shares
- Deferred Share Units
- Filed 2 days after trade
Stock awardEugene A. WoodsDirector
136 shares at $276.31 · $38K
- +2% of holdings
- Now owns 6,579 shares
- Deferred Share Units
- Filed 2 days after trade
Stock awardDaniel E PintoDirector
113 shares at $276.31 · $31K
- +5% of holdings
- Now owns 2,445 shares
- Deferred Share Units
- Filed 2 days after trade
SoldTimothy SchmidEVP, WW Chair, MedTech
33,597 shares at $274.74 · $9.2M
- -57% of holdings
- Now owns 25,447 shares
- Not a pre-planned sale
- 2 transactions
- Filed 2 days after trade
- Also: Option exercise
SoldJennifer L TaubertEVP, WWC. Innovative Medicine
15,000 shares at $263.36 · $4.0M
- -7% of holdings
- Now owns 194,451 shares
- Not a pre-planned sale
- Filed 1 day after trade
- Also: Option exercise
SoldJoaquin DuatoCEO and Chairman of the Board, Director
123,291 shares at $261.17 avg ($261.00 to $262.00) · $32.2M
- -31% of holdings
- Now owns 275,967 shares
- Not a pre-planned sale
- 2 transactions
- Filed 1 day after trade
- Also: Option exercise